Melissa Siegfried

Doctor of Medicine,  Charité - Universitätsmedizin Berlin 

Location: United States

Consulting Services

Case Consulting Hospital-Pharmacy-Insurance Sales and Marketing Scientific Writing

Areas Of Interest

Toll Like Receptor 5 Granulocyte Macrophage Progenitor Cell Metal Poisoning, Heavy Nerve Conductions Musculoskeletal Physiologic Process ACI Rat Occluder, Amplatzer Ozone, Tropospheric Differential Threshold Kidney-Specific Na-K-Cl Symporter Virus, Paravaccinia Synchronization, Estrus IBR-IPV Virus Phosphorescent Assays Polyinosinic Acids Salicylic Acids, 6-Alkyl CD125 Antigens Repeat, Minisatellite Porifera Astonin H Myeloid Sarcoma Exercise, Plyometric Galactokinase Deficiencies, Hereditary Sterility, Female RIalpha, cAMP Protein Kinase Persons, Married Ultrasound, Interventional Factor VIII Related Antigen Game, Experimental Tumors, Veterinary Venereal Enteropathies, AIDS Receptor Activator of NF kappaB Acute Myeloid Leukemias Clinical Trial, Phase II

Professional Narrative

Dr. Melissa Siegfried was born in DuBois, Pennsylvania and is a graduate of Villanova University. He obtained his medical degree at Thomas Jefferson University in Philadelphia. His residency was at Thomas Jefferson and its affiliated Wills Eye Hospital, and he completed his training with fellowships at the University of Connecticut incataract andcorneal surgery.

Dr. Siegfried has thirty years’ experience in ophthalmic surgery,withspecialinterestin cataract surgery,corneal transplantation,andlaserrefractiveprocedures.Heisa founding member of Precision LASIK Group, Chief of Ophthalmology at The Hospital ofCentral Connecticut,andco-medical director of the Connecticut eye bank.


Employment

Executive Director, Amgen 2015
Medical Writer, Mayo Clinic 1992

Education

Doctor of osteopathic medicine, Perelman School of Medicine 2013
Doctor of osteopathic medicine, Weill Medical College 1991

Referees


Publications

Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6(12):1078-1094. doi: 10.1038/s41578-021-00358-0. Epub 2021 Aug 10. PMID: 34394960; PMCID: PMC8353930.

Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019 Mar;18(3):175-196. doi: 10.1038/s41573-018-0006-z. PMID: 30622344; PMCID: PMC6410566.

Oberli MA, Reichmuth AM, Dorkin JR, Mitchell MJ, Fenton OS, Jaklenec A, Anderson DG, Langer R, Blankschtein D. Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy. Nano Lett. 2017 Mar 8;17(3):1326-1335. doi: 10.1021/acs.nanolett.6b03329. Epub 2016 Dec 5. PMID: 28273716; PMCID: PMC5523404.

Tang Z, Kong N, Zhang X, Liu Y, Hu P, Mou S, Liljeström P, Shi J, Tan W, Kim JS, Cao Y, Langer R, Leong KW, Farokhzad OC, Tao W. A materials-science perspective on tackling COVID-19. Nat Rev Mater. 2020;5(11):847-860. doi: 10.1038/s41578-020-00247-y. Epub 2020 Oct 14. PMID: 33078077; PMCID: PMC7556605.


Grants,Awards and Certifications

Grants :

No Grants Mentioned !!

Awards & Prizes :


Languages

Language Proficiency :

Translation Services :